HLA-C locus products are poorly understood in part due to their low expression at the cell surface. Recent data indicate that these molecules serve as major restriction elements for human immunodeficiency virus type 1 (HIV-1) cytotoxic T lymphocyte (CTL) epitopes. We report here a structure-based technique for the prediction of peptides binding to Cw*0401. The models were rigorously trained, tested and validated using experimentally verified Cw*0401 binding and non-binding peptides obtained from biochemical studies. A new scoring scheme facilitates the identification of immunological hot spots within antigens, based on the sum of predicted binding energies of the top four binders within a window of 30 amino acids.
Results
High predictivity is achieved when tested on the training (r2 = 0.88, s = 3.56 kJ/mol, q2 = 0.84, spress = 5.18 kJ/mol) and test (AROC = 0.93) datasets. Characterization of the predicted Cw*0401 binding sequences indicate that amino acids at key anchor positions share common physico-chemical properties which correlate well with existing experimental studies.
Conclusion
The analysis of predicted Cw*0401-binding peptides showed that anchor residues may not be restrictive and the Cw*0401 binding pockets may possibly accommodate a wide variety of peptides with common physico-chemical properties. The potential Cw*0401-specific T-cell epitope repertoires for HIV-1 p24gag and gp160gag glycoproteins are well distributed throughout both glycoproteins, with thirteen and nine immunological hot spots for HIV-1 p24gag and gp160gag glycoproteins respectively. These findings provide new insights into HLA-C peptide selectivity, indicating that pre-selection of candidate HLA-C peptides may occur at the TAP level, prior to peptide loading in the endoplasmic reticulum.
Background
Major histocompatibility complex (MHC) class I molecules, HLA-A, -B, and -C, are cell surface glycoproteins consisting of a polymorphic heavy α chain non-covalently linked to a light chain, β2-microglobulin (β2m). HLA-A and -B molecules play critical roles in cell mediated immune responses by binding short antigenic peptide fragments and presenting them on the surface of antigen-presenting cells for recognition by the CD8+ cytotoxic T lymphocyte (CTL). Although several HLA-C specificities with CTL epitopes have been reported [1, 2], much remains unknown with regards to their role in the immune response against viral antigens in part due to their poor expression at the cell surface [3, 4]. Recent research shows that this group of molecules plays a major role in the control of human immunodeficiency virus type 1 (HIV-1) infection [5]. Improved understanding of peptide binding to this group of molecules is important in the study of HIV-1 disease progression, as well as the design of effective HIV peptide vaccines.
The HLA-C allele, Cw*0401, is of particular interest in the study of HIV-1 disease progression because it is the restriction element for HIV-1 proteins [5]. Two HIV-1 proteins (p24gag and gp160gag) are currently known to be restricted by Cw*0401 [5]. Cw*0401 is present in approximately 10% of the general population [6]. The allele is expressed intracellularly in amounts comparable with HLA-A and -B molecules, but is poorly expressed at the cell surface [7, 8]. Improved understanding of peptide binding to this molecule is important for elucidating its role in HIV-1 disease progression.
Computational strategies for prediction of peptide binding to HLA-A and -B molecules are relatively advanced [9], while sequence-based predictive models for HLA-C molecules have encountered limited success due to the lack of experimental training data [10]. Two matrix-based prediction algorithms for Cw*0401 were reported [11, 12], but a sequence independent approach is still lacking. To overcome these limitations, we have developed a structure-based predictive technique that integrates the strength of Monte Carlo simulations and homology modeling [13–15]. This method utilizes a probe or "base fragment" to sample different regions of the receptor binding site, followed by loop closure and refinement of the entire class I peptide. The technique has been successfully applied to analyze peptides binding to a variety of MHC class II alleles [14, 15]. In this work, we now extend our analysis to peptides presented by the class I HLA-C molecule. We investigated the HIV-1 p24gag and gp160gag peptide binding repertoire of Cw*0401 and illustrate that areas with high concentration of T-cell epitopes or "immunological hot spots" are potentially well distributed throughout both HIV-1 p24gag and gp160gag. We also show that Cw*0401 can possibly bind antigenic peptides in amounts comparable to both HLA-A and -B molecules. Characterization of predicted Cw*0401 binding sequences reveal that Cw*0401 may bind a large variety of amino acids at anchor positions with common physico-chemical properties which correlate well with existing experimental studies [11].
Results and discussion
Cw*0401 predictive model
High predictivity (r2 = 0.88, s = 3.56 kJ/mol, q2 = 0.84, spress = 5.18 kJ/mol) is achieved when tested on the training dataset of 6 Cw*0401 peptide sequences. The Cw*0401 predictive model outperforms the predictive models done by Rognan et al. [16] on training datasets of 5 A*0204 (r2 = 0.85, spress = 2.40 kJ/mol) and 37 2Kk (r2 = 0.78, spress = 3.16 kJ/mol) peptide sequences and is comparable with our previous DRB1*0402 (r2 = 0.90, s = 1.20 kJ/mol, q2 = 0.82, spress = 1.61 kJ/mol) and DQB1*0503 (r2 = 0.95, s = 1.20 kJ/mol, q2 = 0.75, spress = 2.15 kJ/mol) prediction models on a training set of 8 peptides [17]. The cross-validation coefficient q2 and the standard error of prediction spress are stable, with q2 = 0.84 and spress = 5.18 kJ/mol. This iterative regression procedure validates the internal consistency of the scoring function in the current model, rendering it suitable for predictions on the test dataset obtained from biochemical studies. The predictive performance of our model is further validated using the test dataset of 58 peptides. The external validation results indicate that our Cw*0401 predictive model is suitable for discriminating binding ligands from the background with high accuracy (AROC = 0.93) with sensitivity of 76% (SP = 0.95).
Characterization of Cw*0401 binding peptides
An in-depth analysis was performed to investigate the characteristics of Cw*0401 binding peptides. A panel of 2279 sequences was generated using an overlapping sliding window of size 9 across the entire p24gag [5] and gp160gag [18] glycoproteins and modeled into the binding groove of Cw*0401. From these sequences, a total of 877 binding sequences (predicted binders; SE = 76%, SP = 80%) were selected and a systematic analysis was performed to analyze the number of occurrence of individual amino acid residues and physico-chemical properties [19] at each position of Cw*0401 binding peptides.
Peptide position p2 is characterized by alanine (10%), glycine (13%), leucine (9%), serine (9%). 60% of the predicted residues at this position are hydrophobic in nature, while 93% are neutral. These properties correlate with the physico-chemical properties of existing binding motif (Tyr/Phe) at p2 [11] as well as with the observed conservation in the test data (Table 1: Phe – 58% and Tyr – 26%). The p3 position shows a strong preference for glycine (11%) and threonine (8%). Existing anchor residues at this position are aspartic acid and histidine, which accounts for 9% of the total position-specific composition in the dataset. The p4 position shares similar characteristics as p3 (glycine: 9%; threonine: 8%), with additional preference for leucine (8%). Similar results were obtained at the p5 position (alanine: 8%; glycine: 9%; leucine: 8%). At p6, characteristic residues include glycine (9%) and leucine (8%). This position is favored by neutral (81%) acyclic (89%), medium/large (77%), and hydrophobic (51%) residues. The physico-chemical properties of these residues are in agreement with Val/Ile/Leu as reported in earlier studies [11] and is comparable with the conservation in the test dataset reported in Table 1 (Val – 29%, Ile – 12%, Leu and Pro – 10%). Finally, the p9 position was defined by six amino acids, including alanine (8%), glycine (10%), isoleucine (8%), leucine (8%), threonine (9%), and valine (8%). This position is primarily dominated by neutral (90%) and hydrophobic (58%) residues, and agrees with profiles of Leu/Phe as previously reported [11] and is consistent with the conservation in the test dataset reported in Table 1 (Leu and Phe – 39%,). Collectively, our data indicates that individual binding pockets may not be highly specific as previously reported [11] but can rather accommodate a wide-range of anchor residues with common physico-chemical properties. We attribute the discrepancies to two possibilities: i) the lack of extensive research on Cw*0401 peptides; and ii) natural peptides carrying these residues may be present in small amount and were thus not detected by experimental studies.
Table 1
HLA-Cw4 dataset used in this study.
No.
Category
Source
Peptide
IC50 (nM)
Ref.
1
Training Set
Cw3 consensus
FAMPNFQTL
651
24
2
Training Set
Cw6 consensus
IPFPIVRYL
>30000
24
3
Training Set
Cw7 consensus
KYPDFVDAL
2.4
24
4
Training Set
Cw4 consensus
QYDDAVYKL
18
24
5
Training Set
Histone H3.3
RYRPGTVAL
>30000
24
6
Training Set
Unknown Cw6 natural ligand
YQFTGIKKY
>30000
24
7
Test Set
Transcripton factor SUPT4H 56–64
SFDGIIAMM
Binder
10
8
Test Set
Transducin-like 3 120–128
AFDPTSTLL
Binder
10
9
Test Set
UBE3B variant 1 742–750
VFDPALNLF
Binder
10
10
Test Set
XP_173235 3–11
LFDITGQDF
Binder
10
11
Test Set
8 59–67
VYDTNPAKF
Binder
10
12
Test Set
Acyl-CoA synthetase 4 82–90
LFDHAVSKF
Binder
10
13
Test Set
Adenosylhomocyteinehydrolase 566–574
SFDAHLTEL
Binder
10
14
Test Set
ART-1 Adenocarcinoma antigen 21–29
SFDLLPREF
Binder
10
15
Test Set
ATP-binding cassette, sub-family F, member 3 500–508
YYDPKHVIF
Binder
10
16
Test Set
Block of proliferation 1 639–647
SYDSKLVWF
Binder
10
17
Test Set
BM-015 144–152
HFDPEVVQI
Binder
10
18
Test Set
CDC45 541–549
HFDLSVIEL
Binder
10
19
Test Set
Cholesterol acyltransferase 72–80
HFDDFVTNL
Binder
10
20
Test Set
Chromosome 20 open reading frame 40 318–326
FFDNISSEL
Binder
10
21
Test Set
Elongation factor 2 265–273
YFDPANGKF
Binder
10
22
Test Set
Epithelial cell transforming oncogene 21–29
IFDSKVTEI
Binder
10
23
Test Set
Ethanolamine kinase EKI1 132–141
HWDPQEVTL
Binder
10
24
Test Set
Eukaryotic translation initiation factor 3, Su 6 interacting protein 478–486
Prediction of p24gag and gp160gag immunological hot spots
The potential T-cell epitope repertoire (data not shown) and immunological hot spots (Figure 1) for HIV-1 p24gag and gp160gag are well distributed throughout both glycoproteins. The known p24gag epitope (p24 168–175) and gp160gag epitope (gp160 375–383) were successfully predicted by our model at the threshold of -200 (SE = 76%, SP = 80%) [5, 20]. At this threshold, the number of predicted hot spots for p24gag are fourteen (p24 20–75, 89–148, 143–262, 311–381, 447–506, 526–590, 664–727, 708–791, 873–930, 996–1053, 1054–1157, 1157–1316, 1308–1368, and 1378–1427), with an estimated FN = 3, and FP = 3 for SE = 0.76 and SP = 0.95 (Figure 1 and Table 2). For gp160gag we predict nine hot spots (gp160 44–89, 102–171, 174–289, 341–504, 489–559, 581–639, 667–721, 708–766, and 793–852), with an estimated FN = 2, FP = 2 for SE = 0.76 and SP = 0.95 (Figure 1 and Table 3). The results presented here indicate that Cw*0401 can bind antigenic peptides with specificities comparable to HLA-A and -B molecules, and any variability in antigen expression may be directly related to the loss or reduced cell surface expression of the molecule by mechanisms as yet unknown [8, 21].
Table 2
Predicted Cw*0401-specific immunological hotspots for p24gag.
Predicted start positions of Cw*0401-specific hotspots (sliding window size = 30) along (A) p24gag and (B) gp160gag glycoproteins. Scores are computed based on the sum of predicted binding energies of top four binders within the 30 amino acid sliding window. Predicted hotspots regions are shown in blue boxes with experimentally verified regions shown in red.
Conclusion
Due to the low expression of HLA-C molecules at the cell surface, their role in cell mediated immune responses remain poorly understood. Collectively, the outcome of this analysis provides insights into the binding specificities of Cw*0401. Our data strongly indicate that Cw*0401 can bind antigenic peptides in amounts comparable to both HLA-A and -B molecules, and show the existence of a potentially large number of Cw*0401-specific T-cell epitopes that are evenly distributed throughout both HIV-1 p24gag and gp160gag glycoproteins. It remains to be determined what proportion of these peptides may be expressed at the cell surface and capable of eliciting functional responses. Probably, pre-selection of candidate HLA-C peptides may occur at the TAP level, prior to peptide loading in the ER [8]. Consequently, a higher concentration of peptides is necessary for complexation with HLA-C molecules, resulting in their release from TAP. This provides a possible explanation for the reduced cell surface expression of HLA-C molecules [8].
Methods
Data
Crystallographic data
The coordinates of Cw*0401 were obtained from the Protein Databank (PDB) with PDB code 1QQD [22]. The structure was relaxed by conjugate gradient minimization, using the Internal Coordinate Mechanics (ICM) software [23].
Experimental binding data
The dataset comprises a total of 64 (57 binders and 7 non-binders) 9-mer peptides (Table 1). The available dataset is divided into training and testing datasets. Peptides with experimental IC50 values were selected as training data for optimizing the empirical free energy function (refer Empirical Free Energy Function). Due to the lack of experimental data, only 9 peptides with experimental IC50 values were identified, six (three binders and three non-binders) of which were used for training, while the remainder (four non-binders) were included in the test dataset as true negatives. Therefore, the training dataset contained six peptides with experimentally determined IC50 values (2 high-affinity binders, 1 medium-affinity binder, and 3 non-binders) derived from biochemical studies [24], while the testing dataset comprised the remainder 58 peptides (54 binders and 4 non-binders) [10, 18, 21, 24, 25]. Experimental IC50 values were classified as follows – high-affinity binders: IC50 ≤ 500 nM, medium-affinity binders: 500 nM < IC50 ≤ 1500 nM, low-affinity binders: 1500 < IC50 ≤ 5000 nM and non-binders: 5000 < IC50.
HIV-1 sequence data
The sequences of HIV-1 p24gag and gp160gag glycoproteins were obtained from UniProt [26]. The accession numbers for p24gag and gp160gag glycoproteins used in this study are P04585 and P03377 respectively.
Model
Peptide docking
Docking was performed according to the procedure utilized in previous similar works [13–15]: (i) pseudo-Brownian rigid body docking of peptide fragments to the ends of the binding groove, (ii) central loop closure by satisfaction of spatial constraints, and (iii) refinement of the backbone and side-chain atoms of the ligand and receptor contact regions.
Empirical free energy function
The scoring function presented herein is based on the free energy potential in ICM [23]. Computation of the binding free energy was performed according to previous similar work based on the difference between the energy of the solvated complex and the sum of the energy of the solvated receptor and that of the peptide ligand, followed by optimization using experimental IC50 values [15]. This step was followed by 6-fold cross-validation for assessment of quality of the scoring function [15]. In k-fold cross-validation, k random, (approximately) equal-sized, disjoint partitions of the sample data were constructed, and all given models were trained on (k-1) partitions and tested on the excluded partition. The results were averaged after k such experiments, and thus the observed error rate may be taken as an estimate of the error rate expected upon generalization to new data. The predictive power of the models was assessed by the cross-validation coefficient q2 and the standard error of prediction spress.
Immunological hot spot prediction
In this study, 'immunological hot spots' are defined as antigenic regions of up to 30 amino acids and modeled according to previous similar work based on the sum of predicted binding energies of the top four binders within a window of 30 amino acids [27]. Where available, these predicted hotspots were validated with available experimentally determined sites.
Training, testing and validation
The free energy scoring function was calibrated using 6 peptides with experimental IC50 values and tested on a dataset 58 peptides (54 binders and 4 non-binders) obtained from biochemical studies (Table 1). The predictive performance of our model was assessed using sensitivity (SE), specificity (SP) and receiver operating characteristic (ROC) analysis [28]. SE = TP/(TP+FN) and SP = TN/(TN+FP), indicate percentages of correctly predicted binders and non-binders, respectively. TP (true positives) represents correctly predicted experimental binders and TN (true negatives) for experimental non-binders incorrectly predicted as binders. FN (false negatives) denotes experimental binders predicted as non-binders and FP (false positives) stands for experimental non-binders predicted as binders. The accuracy of our predictions was assessed by the ROC analysis where the ROC curve is generated by plotting SE as a function of (1-SP) for a complete range of classification thresholds. The area under the ROC curve (AROC) provides a measure of overall prediction accuracy, AROC < 70% for poor, AROC > 80% for good and AROC > 90% for excellent predictions [15].
Abbreviations
CTL:
cytotoxic T lymphocyte
HLA:
human leukocyte antigen
MHC:
major histocompatibility complex
ER:
endoplasmic reticulum
HIV:
human immunodeficiency virus
ROC:
receiver operating characteristic
SE:
sensitivity
SP:
specificity
TN:
true negative
TP:
true positive
FN:
false negative
FP:
false positive
Declarations
Acknowledgements
This work was partly funded by the National Institute of Allergy and Infectious Diseases, National Institute of Health, USA (Grant #5 U19 AI56541 & Contract #HHSN266200400085C).
Authors’ Affiliations
(1)
Institute for Infocomm Research
(2)
Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore
(3)
Department of Pharmacology and Molecular Sciences, John Hopkins University School of Medicine
(4)
Cancer Vaccine Center, Dana-Farber Cancer Institute
(5)
Department of Chemistry and Biomolecular Sciences & Biotechnology Research Institute, Macquarie University
References
Dill O, Kievits F, Koch S, Ivanyi P, Hämmerling GJ: Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice.Proc Natl Acad Sci USA 1988, 85:5664–5668.View ArticlePubMedGoogle Scholar
Littaua RA, Oldstone MB, Takeda A, Debouck C, Wong JT, et al.: An HLA-C-restricted CD8+cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag.J Virol 1991, 65:4051–4056.PubMedGoogle Scholar
Snary D, Barnstable CJ, Bodmer WF, Crumpton MJ: Molecular structure of human histocompatibility antigens: the HLA-C series.Eur J Immunol 1977, 8:580–585.View ArticleGoogle Scholar
McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P: Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA.J Exp Med 1995, 181:2085–2095.View ArticlePubMedGoogle Scholar
Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, Walker BD, Watkind DI: HIV Molecular Immunology 2005. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico 2005.Google Scholar
Bugawan TL, Klitz W, Blair A, Erlich HA: High-resolution HLA class I typing in the CEPH families: analysis of linkage disequilibrium among HLA loci.Tiss Antigens 2000, 56:392–404.View ArticleGoogle Scholar
Neefjes JJ, Ploegh HL: Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with β2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association.Eur J Immunol 1988, 18:801–810.View ArticlePubMedGoogle Scholar
Neisig A, Melief CJ, Neefjes J: Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction.J Immunol 1998, 160:171–179.PubMedGoogle Scholar
Brusic V, Bajic VB, Petrovsky N: Computational methods for prediction of T-cell epitopes – a framework for modelling, testing, and applications.Methods 2004, 34:436–443.View ArticlePubMedGoogle Scholar
Buchsbaum S, Barnea E, Dassau L, Beer I, Milner E, Admon A: Large-scale analysis of HLA peptides presented by HLA-Cw4.Immunogenetics 2003, 55:172–176.View ArticlePubMedGoogle Scholar
DeLuca DS, Khattab B, Blasczyk R: A modular concept of HLA for comprehensive peptide binding prediction.Immunogenetics 2007, 59:25–35.View ArticlePubMedGoogle Scholar
Tong JC, Tan TW, Ranganathan S: Modeling the structure of bound peptide ligands to major histocompatibility complex.Protein Sci 2004, 13:2523–2532.View ArticlePubMedGoogle Scholar
Tong JC, Bramson J, Kanduc D, Chow S, Sinha AA, Ranganathan S: Modeling the bound conformation of pemphigus vulgaris-associated peptides to MHC class II DR and DQ alleles.Immunome Res 2006, 2:1.View ArticlePubMedGoogle Scholar
Tong JC, Zhang GL, Tan TW, August JT, Brusic V, Ranganathan S: Prediction of HLA-DQ3.2βligands: Evidence of multiple registers in class II binding peptides.Bioinformatics 2006, 22:1232–1238.View ArticlePubMedGoogle Scholar
Rognan D, Laumøller SL, Holm A, Buus S, Tschinke V: Predicting binding affinities of protein ligands from three-dimensional models: Application to Peptide Binding to Class I Major Histocompatibility Proteins.J Med Chem 1999, 42:4650–4658.View ArticlePubMedGoogle Scholar
Johnson RP, Trocha A, Buchanan TM, Walker BD: Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone.J Virol 1993, 67:438–445.PubMedGoogle Scholar
Brander C, Goulder PJR: Recent advances in HIV-1 CTL epitope characterization. In HIV molecular immunology database.HIV Molecular Database(Edited by: Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, Walker BD, Watkind DI). Los Alamos National Laboratory. Los Alamos, New Mexico 1999, i1-i19.Google Scholar
Buseyne F, Stevanovic S, Rammensee HG, Riviere Y: Characterization of an HIV-1 p24gag epitope recognized by a CD8+ cytotoxic T-cell clone.Immunol Letters 1997, 55:145–149.View ArticleGoogle Scholar
Fan QR, Wiley DC: Structure of Hla-Cw4, a Ligand for the Kir2D Natural Killer Cell Inhibitory Receptor.J Exp Med 1999, 190:113–124.View ArticlePubMedGoogle Scholar
Abagyan RA, Totrov M: Ab initio folding of peptides by the optimal-bias Monte Carlo minimization procedure.J Comput Phys 1999, 151:402–421.View ArticleGoogle Scholar
Sidney J, del Guercio MF, Southwood S, Engelhard VH, Appella E, Rammensee HG, Falk K, Rötzschke O, Takiguchi M, Kubo RT, Grey HM, Sette A: Several HLA alleles share overlapping peptide specificities.J Immunol 1995, 154:247–259.PubMedGoogle Scholar
Rajagopalan S, Long EO: The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity.J Exp Med 1997, 185:1523–1528.View ArticlePubMedGoogle Scholar
The UniProt Consortium: The Universal Protein Resource (UniProt).Nucleic Acids Res 2007, 35:D193-D197.View ArticleGoogle Scholar
Srinivasan KN, Zhang GL, Khan AM, August JT, Brusic V: Prediction of class I T-cell epitopes: evidence of presence of immunological hot spots inside antigens.Bioinformatics 2004, 20:i297-i302.View ArticlePubMedGoogle Scholar
Bradley AP: The use of the area under the ROC curve in the evaluation of machine learning algorithms.Pattern Recognition 1997, 30:1145–1159.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
